

## COVID-19 GRANT FUNDING OPPORTUNITIES

---

### Biomedical Advanced Research and Development Authority (BARDA)

Portal for the 2019 novel coronavirus (COVID-19) medical countermeasures task force as a single point of entry for the submission of market research packages and meeting requests from interested stakeholders. Do You Have a COVID-19 Medical Countermeasure in Development? You should be:

- Progressed into or beyond non-clinical trials
- Established large scale cGMP manufacturing capability . . .
- . . . Or utilize an approved platform
- Focus: Diagnostics; Therapeutics; Vaccines; or other

**See:** <https://beta.sam.gov/opp/d1b6e601426e4e4c943235babdd4133a/view>

**Topic:** Products to diagnose, prevent or treat novel coronavirus infections

**Due Date:** Rolling, through October 31, 2020

**Award:** Unlimited

**Application: Register - Login - Submit:** Brief Description; Slide Deck; Manuscript; Publications; Other Non-Confidential

**See:** <https://www.medicalcountermeasures.gov/App/CreateUserWizard.aspx> to Register with TechWatch

**See Also:** <https://www.medicalcountermeasures.gov/Request-BARDA-TechWatch-Meeting>

TechWatch Meeting Benefits/Aim: (1) Gain Visibility (2) Get Feedback from Experts (3) Hear Techniques & Strategies to Handle Challenges (4) Get Insight on How to Position Your Solution (5) Prepare for a Formal Proposal Submission

---

### BARDA Division of Research, Innovation & Ventures (DRIVE) BAA

**See:** <https://drive.hhs.gov/>

**Topics:** Diagnostic assays, screening and model development, vaccines, advanced manufacturing

**Due Date:** Abstract submissions due by 5PM ET on June 30, 2020

**Awards:** Up to \$750,000

---

### National Institutes of Health (NIH)

#### Notices of Special Interest (NOSI)

Several NIH Institutes have issued a **Notice of Special Interest (NOSI)** to provide funding for research topics related to COVID-19.

- NOT-AG-20-022 - National Institute on Aging (NIA); Mental Health (NIMH)
- NOT-HG-20-030 - National Human Genome Research Institute (NHGRI)
- NOT-ES-20-016 - National Institute of Environmental Health Sciences (NIEHS)
- NOT-TR-20-012 - National Center for Advancing Translational Sciences (NCATS)
- NOT-AI-20-034 - National Institute of Allergy and Infectious Diseases (NIAID)
- NOT-AI-20-040 - National Institute of Allergy and Infectious Diseases (NIAID)
- NOT-GM-20-025 - National Institute of General Medical Sciences (NIGMS)
- NOT-TR-20-011 - National Center for Advancing Translational Sciences (NCATS)
- NOT-DA-20-047 - National Institute on Drug Abuse (NIDA)
- NOT-HL-20-757 - National Heart, Lung, and Blood Institute (NHLBI)

**See:** <https://grants.nih.gov/policy/natural-disasters/corona-virus.htm>

**NIH Conditions: PA-18-591 - Administrative Supplements to Existing NIH Grants** and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional); **PA-18-935 Urgent Competitive Revision to Existing NIH Grants** and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

You are strongly encouraged to contact the listed NOSI Program Staff to discuss your proposed research/aims to confirm that your aim is appropriate and of interest.

**Each NOSI Presents with Specific Requisites.**

**FOR EXAMPLE: the NIA and NIMH (NOT-AG-20-022)**

See: <https://grants.nih.gov/grants/guide/notice-files/NOT-AG-20-022.html>

Aim: Understand and Control COVID-19

Expiration: May 1, 2020 (Other dates vary per agency)

Specific Application & Submission Information

- **PA-18-591: Administrative Supplements to Existing Grants**
- **PA-18-935: Urgent Competitive Revision to Existing Grants**
- **Grants Must Be Active (not Extensions)**
- Accepted on a Rolling Basis
- Period of Award = 6 Months - 1 Year

---

**National Heart, Lung, Blood Institute (NHLBI)**

**Notice Number: NOT-HL-20-757**

Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

See: <https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-757.html>

**Research Objectives:** To better understand the host response, associated HLB disease, impact on transfusion safety, and short- and long-term clinical outcomes of individuals infected with SARS-CoV-2. Of interest are studies that take advantage of human research or unique model systems to study the consequences of SARS-CoV-2 infection. Supported research is expected to inform future efforts to diagnose, prevent, mitigate, or treat this viral infection and associated HLB manifestations. (See the above link for specific interest topics.)

**Due Date:** Rolling, through October 6, 2020

**Budget:** Not specified

**Conditions:** **PA-18-591 - Administrative Supplements to Existing NIH Grants** and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional); **PA-18-935 Urgent Competitive Revision to Existing NIH Grants** and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

---

**National Institute of Allergy and Infectious Diseases (NIAID)**

**Notice Number: NOT-AI-20-034** - Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

**Notice Number: NOT-AI-20-040** - Notice of Early Expiration of "Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)," NOT-AI-20-030

- Expiration: March 25, 2021
- Specific Application & Submission Information
- **PA-20-135: Urgent Competitive Revision to Existing Grants**
- Expand the Scope of Existing Awards
- Limit Research Strategy to 6 Pages
- Accepted on a Rolling Basis
- Period of Award = 2 Years

See: <https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-034.html>

**See Also:** <https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-040.html>

**Due Date:** Rolling until March 25, 2021

**Awards:** Not Specified

---

#### **National Institute of General Medical Sciences (NIGMS)**

**Notice Number: NOT-GM-20-025:** Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2

**Interests:** (1) Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants). (2) Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only). (3) Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only).

**See:** <https://grants.nih.gov/grants/guide/notice-files/NOT-GM-20-025.html>

**Due Date:** Rolling, through February 6, 2021

**Awards:** Not Specified

---

#### **National Center for Advancing Translational Sciences (NCATS)**

**Notice Number: NOT-TR-20-012:** Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., "coronavirus disease 2019" (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.

**See:** <https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-012.html> (National Center for Expires: October 17, 2020

**See Also:** NOT-TR-20-011 - <https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-011.html>

**Expires:** July 10, 2021

---

#### **National Institute of Environmental Health Sciences (NIEHS)**

**NOSI Notice Number: NOT-ES-20-017:** NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed)

**Aim:** The purpose of this supplement is to provide support for the conduct of worker-based training to prevent and reduce exposure of hospital employees, emergency first responders, and other workers who are at risk of exposure to Coronavirus through their work duties.

**Due Date:** April 25, 2020

**See:** <https://grants.nih.gov/grants/guide/notice-files/NOT-ES-20-017.html>

**Eligibility:** Applicants must be an active grantee of (1) RFA-ES-14-008, "Hazardous Materials Worker Health and Safety Training (U45 Clinical Trials Not Allowed)", (2) RFA-ES-14-009, "HAZMAT Training at DOE Nuclear Weapons Complex (UH4 Clinical Trial Not Allowed)", (3) RFA-ES-15-018, "Worker Training Program (WTP) Ebola Biosafety and Infectious Disease Response Training (UH4)", or (4) RFA-ES-17-004, RFA-ES-18-006, RFA-ES-19-009 - SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed).

---

#### **National Institute of Drug Abuse (NIDA)**

**Notice Number: NOT-DA-20-047 -** Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

**Aim:** NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

**See:** <https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-047.html>

**Due Date:** Rolling, through March 31, 2021

**Budget:** Maximum of \$100,000 direct costs per year for 2 years. Higher budgets may be considered with justification.

---

### **National Human Genome Research Institute (NHGRI)**

**Notice Number:** NOT-HG-20-030 – Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

**Topics:** Genomic studies utilizing generalized approaches that take advantage of human research or model systems to study the consequences of SARS-CoV-2 infection. Supported research is expected to guide and inform future efforts to diagnose, prevent, mitigate, or treat this viral infection.

**See:** <https://grants.nih.gov/grants/guide/notice-files/NOT-HG-20-030.html>

- Aim: Understand and Control COVID-19
- Expiration: May 16, 2020
- Specific Application & Submission Information
- PA-18-591: Administrative Supplements to Existing Grants
- PA-18-935: Urgent Competitive Revision to Existing Grants
- Grants Must Be Active (INCLUDING Extensions)
- Budget No Greater Than \$250,000 (Unless Justified)
- Accepted on a Rolling Basis
- Period of Award = 1 Year

#### Related Announcements:

**PA-18-935** Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional) is intended to provide funds for NIH grantees applying to expand the scope of their active grant.

**PA-18-591** Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) is intended to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant.

---

### **National Institute on Deafness and Other Communication Disorders (NIDCD)**

**NOSI Notice Number:** NOT-DC-20-004 - Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19)

**Aim:** NIDCD is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in relation to NIDCD's scientific mission areas of hearing, balance, taste, smell, voice, speech and language.

**Interests:** In order to rapidly improve our understanding of the infection of SARS-CoV-2 and of COVID-19, NIDCD is encouraging the submission of applications for supplements to active NIDCD grants to address the pathology, prevention, diagnosis, sequelae, or treatment of COVID-19 directly related to NIDCD's mission areas.

**Due date:** Rolling through 6/2/2020

**Budget:** \$125,000 Direct Costs

Memo: Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.

- PA-18-591 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

---

### **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)**

**Notice of Special Interest (NOSI):** Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK

**Aim:** NIDDK is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). NIDDK is particularly interested in projects focusing on the direct action of the virus on kidney, gastrointestinal tract function, and the endocrine/metabolic system, and the collection of bio samples that will inform the understanding of renal, gastrointestinal, and endocrine/metabolic sequelae of viral infection. Pilot clinical studies (observational and interventional) that support the understanding or treatment of COVID-19-related diseases within the mission of the NIDDK are also of interest. NIDDK will only consider applications that propose projects that may lead to rapid translation and impact in the COVID-19 emergency to be responsive.

**See:** <https://grants.nih.gov/grants/guide/notice-files/NOT-DK-20-018.html>

**Due Date:** Rolling through June 2, 2020

**Budget:** Lesser of current year direct cost budget or \$500,000

---

### **National Institute of Biomedical Imaging and Bioengineering (NIBIB)**

NIBIB has issued a shared set of topics and three separate NOSIs for current grantees, SBIR/STTR applicants, and all other applicants:

**Interests:** Rapid diagnostics, wearable/implantable sensors, digital health platforms, healthcare training platforms, robotic technologies to limit caregiver exposure, ventilators, and disinfectant technologies

**See:** <https://www.nibib.nih.gov/>

**See Also:** "NIH begins study to quantify undetected cases of coronavirus infection":

<https://www.nibib.nih.gov/news-events/newsroom/nih-begins-study-quantify-undetected-cases-coronavirus-infection>

**See Also:** "Social engineering and bioengineering together can thwart the COVID-19 pandemic":

<https://www.nibib.nih.gov/about-nibib/directors-corner>

**Due Date:** Varies

**Awards:** Varies

---

### **National Institute of Neurological Disorders and Stroke (NINDS)**

**Notice Number: NOT-NS-20-046** - Notice of Special Interest regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for the Establishment and Maintenance of a Research Database for Neurological Manifestations of the SARS-CoV-2

**Interests:** NINDS is especially interested in developing systems to collect data on the neurologic effects of COVID-19 infection in patients requiring intensive care and less severely affected individuals seen by health care practitioners.

- In order to rapidly improve our understanding of the prevalence and symptomatology of SARS-CoV-2 neurologic involvement, NINDS is encouraging the submission of applications for Competitive Revisions and Administrative Supplements to active grants to establish and

maintain a database that collects clinical information on the neurological manifestations of SARS-CoV-2

- Rapid establishment and deployment of a web-based portal for individual practitioners and institutions to enter de-identified data on neurological complications in COVID-19 patients. Data must be collected using established standards and Common Data Elements (CDEs).
- Establishment of a Global Unique Identifier (GUID) for patients entered into a COVID-19 NeuroDatabase to enable linkage to other GUID-enabled clinical research on the same individual.
- Establishment and maintenance of a COVID-19 NeuroDatabase to harmonize, aggregate and make the collected data widely available and useful for analysis, following the FAIR (Findable, Accessible, Interoperable, Reusable) Guiding Principles. To ensure maximal value of the project, applicants are expected to use open-source tools for harmonization and curation whenever possible.

**Due Date:** May 9, 2020

**Awards:** Not specified

#### **NIH NOTES:**

- (1) You are strongly encouraged to contact the listed NOSI Program Staff to discuss your proposed research/aims to confirm that your aim is appropriate and of interest.
- (2) UPDATE: NIH Late Application Policy Due to Public Health Emergency for United States for 2019 Novel Coronavirus (COVID-19). Grant applications submitted late for due dates between March 9, 2020 and May 1, 2020, will be accepted through May 1, 2020.
- (3) General Frequently Asked Questions (FAQs) - Proposal Submission and Award Management Related to COVID-19. **See:** <https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-083.html>
- (4) Flexibilities Available to Applicants and Recipients of Federal Financial Assistance Affected by COVID-19. **See:** <https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-086.html>

---

## **National Science Foundation (NSF)**

### **Division of Innovation & Industrial Partnerships - Engineering Directorate**

**Invitation:** Phase I Proposals

**Dear Colleague Letter** on the Coronavirus: Request for SBIR/STTR Phase I Proposals Addressing COVID-19 (NSF 20-065 Issued: March 25, 2020)

**See:** [https://www.nsf.gov/pubs/2020/nsf20065/nsf20065.jsp?mc\\_cid=75fccb9230&mc\\_eid=86d29f650d](https://www.nsf.gov/pubs/2020/nsf20065/nsf20065.jsp?mc_cid=75fccb9230&mc_eid=86d29f650d)

**Areas of Research Interest:** Artificial Intelligence, Digital Health, Diagnostics, Distributed Ledger, Environmental Technologies, Medical Devices, Pharmaceutical Technologies, Disinfection & Sterilization, Filtration & Separations.

**Follow Standard Guidelines:** This includes a Required Project Pitch. Companies who already have an active SBIR/STTR award - submit a Project Pitch first. When Submitting a Project Pitch:

- Select "COVID-19" as the SBIR/STTR topic area on the Project Pitch form (see: <https://nsfgov.secure.force.com/sbir/>)
- Reference the word "COVID-19" and the Dear Colleague Letter (NSF 20-065) in the "Describe the Technology/Innovation" field
- See: <https://www.nsf.gov/pubs/2020/nsf20065/nsf20065.jsp>

- (1) Submit Your NSF SBIR/STTR proposals through Fastlane
- (2) Follow the NSF SBIR and STTR Phase I solicitation guidelines
- (3) The term "COVID-19" must be in the proposal title



- (4) Expedite Your Submission and Review – Make your project description closer to Nine-Pages (the maximum is fifteen pages)
- (5) You must have an active registration with the System for Award Management, (at SAM.gov) to register in Research.gov & prepare a proposal.
- (6) SAM.gov registration is not needed to submit a Project Pitch but can take weeks to get.
  - Proposals Responding to this DCL: Reviewed according to NSF SBIR/STTR Merit Review Criteria (Intellectual Merit, Broader Impacts, and Commercial Impact)
  - **See:** NSF: Peer Review Guidelines <https://seedfund.nsf.gov/resources/review/peer-review/>
  - Awards Within Six Weeks of Proposal Receipt
  - The NSF encourages investigators to use existing NSF funding mechanisms to submit proposals to conduct non-medical, non-clinical-care research that can be used immediately

---

**Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19) - (NSF 20-056; March 5, 2020)**

**View Letter & Instructions:** <https://www.nsf.gov/pubs/2020/nsf20055/nsf20055.jsp?org=NSF>

Through this DCL, the Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting **RAPID proposals and supplemental funding requests to existing awards** that address COVID-19 challenges through data and/or software infrastructure development activities. Such activities would be funded by the Computational and Data-Enabled Science and Engineering (CDS&E) program or the Cyberinfrastructure for Sustained Scientific Innovation (CSSI) program.

**NSF Interest:** NSF's interest in accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to better understand how to model and understand the spread of COVID-19; to inform and educate about the science of virus transmission and prevention; and to encourage the development of processes and actions to address this global challenge.

**Proposal Directions:** Before submitting a RAPID proposal or supplemental funding request in response to this DCL, investigators must first contact one of the cognizant OAC program officers listed below in order to determine whether the proposed activities meet NSF guidelines for these types of submissions.

**Budget and Submission:** Contact Office of Advanced Cyberinfrastructure program directors

**See Also:** NSF 20-052 Dear Colleague Letter on the Coronavirus Disease 2019 (COVID19) Revised April 3, 2020 (<https://www.nsf.gov/pubs/2020/nsf20052/nsf20052.pdf>)

---

**U. S. Air Force**

**SBIR Commercial Solutions Opening (CSO) AF Ventures Direct-to-Phase II**

AFWERX - <https://www.afwerx.af.mil/sbir.html>

Direct to Phase II: COVID-19 FOCUS AREA INTERESTS

- (1) Focus Area 1: Decision Support in Combating the Virus (Social Media Analytics; Adware Proximity Algorithm; Mobile Application for Self-Reporting; Enterprise Tool for COVID Tracking)
- (2) Focus Area 2: Personnel Needs (Tele-Ministry; Tele-Counseling; Tele-Health; ChatBots)
- (3) Focus Area 3: Readiness (Readiness Impact Assessment Tools; Training Scheduling Optimization)
- (4) Focus Area 4: Logistics (Medical Resources Common Operation Picture)
- (5) Focus Area 5: Medical (Antiviral Surface Coatings – for Cleansing; Field Deployable COVID-19 Test Kits; Dual Patient Ventilator Modification; Medical Supply Chain, Additive Manufacturing)

**Due Date:** Application Period Ends April 30:

**Directions:** Send an Email to COVID@afwerz.af.mil w/ subject line "SBIR 20-R-[Your Firm Name]" w/ a Brief Description of Your Proposed Solution

**Budget:** \$1,000,000 (Can exceed amount with matching Government funds)

---

### **Medical CBRN Defense Consortium**

**"Other Transaction Agreements [or Authority]" (OTA) for Industry, Academic, & NFP Partners**  
(Single Entity or Group)

**See:** <https://www.medcbrn.org/>

**You need to join the MCDC. See:** <https://www.medcbrn.org/how-to-join/>

**Facilitates** Chemical, Biological, Radiological & Nuclear Defense Partnership Agreements between MCDC Members & the U. S. Joint Program Medical Countermeasures Systems (MCS) Office

#### **Technical Areas of Interest (Examples):**

- Therapy Medical Counter Measure (MCM) prototypes targeting Viral, Bacterial, & Biological Toxins & other
- Single and multiple-drug auto injector delivery devices
- Vaccine-Manufacturing Platforms
- Prototypes for the prophylaxis, treatment and diagnosis of CBRN threats, including Acute Radiation Syndrome & chemical nerve agents
- Systems to increase the speed, accuracy, and confidence of Agent Identification and Disease Diagnosis
- Advanced Development & Manufacturing capabilities

**Solicitations:** <https://www.medcbrn.org/solicitations/> Members receive Requests for Prototype Proposals (RPP), but proposal overtures may be initiated.

---

### **Medical Technology Enterprise Consortium (MTEC)**

#### **Development of Treatments for COVID-19**

MTEC is an enterprise partnership in collaboration with industry and academia to facilitate research and development activities, in cooperation with the U.S. Army Medical Research and Development Command (USAMRDC) and other DoD agencies in the biomedical sciences MTEC membership is not required for proposal submission, but it is required for an award.

**See:** <https://www.mtec-sc.org/>

**Current Opportunity:** MTEC has released a Request for Project Proposals (RPP) for the National Emergency Telecritical Care Network (NETCCN) Project.

**Active Solicitations - See:** <https://www.mtec-sc.org/solicitations/>

**Solicitation Number:** MTEC-20-10-COVID-19 NETCCN TATRC "National Emergency Telecritical Care Network (NETCCN)" - <https://www.mtec-sc.org/wp-content/uploads/2020/04/20-10-COVID-19-NETCCN.pdf>; Sponsor: Telemedicine & Advanced Technology Research Center (TATRC)

**Due Date:** April 27, 2020 (Enhanced White Paper Due Date: April 27, 2020 Noon Eastern Time Zone)

---

### **BRO-20-NEWTON: DoD Newton Award for Transformative Ideas during the COVID-19 Pandemic**

**See:** <https://www.grants.gov/web/grants/view-opportunity.html?oppld=326034>

**Topic:** This award will be presented to a single investigator or team of up to two investigators that develops a "transformative idea" to resolve challenges, advance frontiers, and set new paradigms in areas of immense potential benefit to DoD and the nation at large.

- Deadline for Proposals: Rolling through May 15, 2020
- Given to a Single Investigator (or 2-Person Team)
- DoD will only cover salary, fringe benefits & indirect costs.
- The Period of Performance: 6 months.



- Up to 10 Awards

**Due Date:** May 15, 2020

**Award Amount:** Not to exceed \$50,000 per investigator or \$100,000 for a collaborative proposal by two investigators.

---

### **Agency for Healthcare Research & Quality (AHRQ)**

**Notice of Intent NOT-HS-20-008** - Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19

**See:** <https://www.ahrq.gov/news/funding-opportunities-covid-19.html>

- (1) **Competitive Revision Supplements to Existing AHRQ Grants** and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (NOT-HS-20-007: \$2.5 M)
- (2) **Revision Supplements to Existing AHRQ Grants** and Cooperative Agreements to Address Health System Responsiveness to COVID-19
- (3) **ALSO: Novel, High-Impact Studies** Evaluating Health System and Healthcare Professional Responsiveness to COVID-19 (NOT-HS-20-008: <https://grants.nih.gov/grants/guide/notice-files/NOT-HS-20-008.html>) – Special Interest: Digital Health Innovations, Telemedicine

**Aim:** The health systems research community should prepare to submit applications to AHRQ to fund critical research focused on evaluating topics such as innovations and challenges encountered in the rapid expansion of telemedicine in response to COVID-19, effects on quality, safety, and value of health system response to COVID-19, and the role of primary care practices and professionals during the COVID-19 epidemic. AHRQ is particularly interested in understanding how digital health innovations contributed to health system and healthcare professional innovation and challenges and solutions to meeting the needs of vulnerable populations including older adults, people living with multiple chronic conditions, rural communities, and uninsured and underinsured populations.

**Award Budget:** \$5.0 Million

**Submission:** AHRQ is working to publish the FOA in early May 2020 with submissions due in June 2020.

---

### **US Department of Agriculture (USDA)**

**National Institute of Food and Agriculture (NIFA)**

**USDA Rapid Response to Novel Coronavirus (SARS-CoV-2) Impacts Across Food and Agricultural Systems Program Area**

**View Solicitation:** <https://nifa.usda.gov/funding-opportunity/agriculture-and-food-research-initiative-foundational-applied-science-program>

**Aim:** Develop and deploy rapid, reliable, and readily adoptable strategies across the food and agriculture enterprise in response to the COVID-19 pandemic.

**Interests:** Innovations should mitigate urgent threats from the COVID-19 virus (SARS-CoV-2) and ensure the availability of an accessible, safe, nutritious, and abundant food supply. Proposals should provide solutions to include tools, techniques, technologies, food supply logistics, innovations, and other practices that can be rapidly adopted by end-users.

**See:** "Agriculture and Food Research Initiative Competitive Grants Program": 4/16/2020 Modification Pages: 72-75 (new program area priority) - <https://nifa.usda.gov/sites/default/files/rfa/FY-2020-AFRI-Foundational-and-Applied-Science-RFA-modified-4-16-2020.pdf>

**Due Date:** June 4, 2020

**Budget:** \$192,600,000

**Awards:** Up to \$1,000,000

---

### **USDA Small Business Innovation Research (SBIR)**

**Funding Opportunity Number:** USDA-NIFA-SBIR-007374

<https://nifa.usda.gov/funding-opportunity/small-business-innovation-research-program-phase-i>

**Topic:** Projects dealing with agriculturally related manufacturing and alternative and renewable energy technologies are encouraged across all SBIR topic areas. USDA SBIR's flexible research areas ensure innovative projects consistent with USDA's vision of a healthy and productive nation in harmony with the land, air, and water.

**Specific:** Proposed Projects must include "COVID-19 Rapid Response" in the title.

**Due Date:** May 21, 2020

**Budget:** \$25,000,000

**Awards:** Funds may be awarded up to \$100,000 for a Phase I project.

---

### **USDA Distance Learning and Telemedicine (DLT) Grant**

**Funding Opportunity Number:** RUS-20-02-DLT

**Division:** United States Department of Agriculture, Rural Development, Rural Utilities Service

**See:** [https://www.rd.usda.gov/sites/default/files/USDARUS2020\\_DLT\\_FOAR2CARESActFunding\\_04142020.pdf](https://www.rd.usda.gov/sites/default/files/USDARUS2020_DLT_FOAR2CARESActFunding_04142020.pdf)

**Aim:** DLT grant funds support the use of telecommunications-enabled information, audio and video equipment, and related advanced technologies by students, teachers, medical professionals, and rural residents. These grants are intended to increase rural access to education, training, and health care resources that are otherwise unavailable or limited in scope.

**Due Date:** July 13, 2020

**Budget:** \$25,000,000

**Awards:** \$50,000 – \$1,000,000

---

### **Department of Commerce**

**National Institute of Standards and Technology (NIST)**

**NIST Manufacturing USA National Emergency Assistance Program**

**See:** <https://www.grants.gov/web/grants/search-grants.html?keywords=2020-NIST-MFGUSA-NEAP-01>

**Aim:** NIST invites Manufacturing USA institutes to propose high-impact projects designed to respond to the COVID-19 pandemic.

**Topic:** Projects should focus on responding to the COVID-19 pandemic. Projects may include medical countermeasures; non-medical countermeasures; leveraging institute capabilities to strengthen state and community resilience; grants to companies and technical support to accelerate productions of critical materials, equipment, and supplies; creation of additional production facilities; technology road mapping for pandemic response and recovery; reshoring the manufacture of critical conventional drugs and ensuring supply chain for critical materials related to pandemic response; or workforce development and training for a skilled advanced manufacturing workforce.

**Due Date:** Applications for funding pursuant to this NOFO will be reviewed and considered on a rolling basis as they are received. Applications will be accepted until an amendment indicating 90 days to close this NOFO, subject to the publication of a superseding NOFO. Funding is subject to availability.

**Current Closing Date for Applications:** Not stated

**Awards:** Not stated

---

### **Other Agencies and Entities**

**xTech COVID-19 Ventilator Challenge –**

**See:** <https://www.challenge.gov/challenge/xTech-COVID-19-ventilator-challenge/>

**Aim:** Develop a low-cost, readily manufacturable emergency ventilator to quickly augment ventilator capacity during the COVID-19 pandemic.

**Interest:** The U. S. Army Acquisition Executive is launching the xTech: COVID-19 Ventilator Challenge to all innovators across the nation. The Army solicits the innovation community's ideas for combatting this unprecedented modern pandemic.

**Terms:** The prize competition will evaluate technology proposals immediately upon submission and award novel solutions with a prize of \$5,000 to present a virtual pitch of the technology concept to the xTech COVID-19 panel, and award prizes of \$100,000 to solutions accepted by the panel to develop a concept prototype. Select technologies may receive follow on contracts for additional production and deployment.

**Submission:** Rolling Submission through May 31, 2020

**Awards:** \$5,000 if invited to pitch; \$100,000 if awarded

---

### **Pfizer COVID-19 Competitive Grant Program – Solutions for Healthcare Providers:**

#### **Category A (Medical Education) & Category B (Quality & Process Improvement)**

**See:** [https://pfe-pfizercom-prod.s3.amazonaws.com/GMG\\_2020GMG\\_G-COVID-19.pdf](https://pfe-pfizercom-prod.s3.amazonaws.com/GMG_2020GMG_G-COVID-19.pdf)

**Category A:** Independent Medical Education Grants – Support educational programs for healthcare providers focused on the recognition, diagnosis, treatment, and overall care management of patients with COVID-19.

**Category B:** Quality & Process Improvement Grants – provide support to hospitals or healthcare systems so that they may evaluate and improve their systems-of-care for COVID-19 patients. Funds can be used for staff training or clinical process improvement.

**Due Date:** May 22, 2020

**Awards:** Up to \$250,000

**See Also:** <https://www.pfizer.com/purpose/independent-grants/competitive-grants>

---

### **Coalition for Epidemic Preparedness Innovation (CEPI)**

Multi-purpose platform technologies for rapid response against emerging infectious diseases: CEPI issues calls for proposals and requests for information inviting applicants to submit proposals for projects to develop vaccine candidates and support clinical trials involving vaccine candidates.

**See:** [https://cepi.net/get\\_involved/cfps/](https://cepi.net/get_involved/cfps/)

**Topic:** Vaccine and adaptive epidemic response platform development - Centralized laboratory for measurement of immune responses elicited by SARS-CoV-2 vaccine candidates

**Aim:** Comparing immune responses against different vaccine candidates intended for the prevention of the novel virus responsible for Coronavirus Disease 2019 (COVID-19)

**Due Date:** Submit applications in PDF format within max 10 pages to [centralizedlab@cepi.net](mailto:centralizedlab@cepi.net) before 15:00 CET on Sunday 10 May 2020. **See Application Template:** [https://cepi.net/get\\_involved/cfps/](https://cepi.net/get_involved/cfps/) ("How to Apply")

**Budget:** Open

---

### **MIT - Elevate Prize Foundation - Health Security & Pandemics Challenge**

**Aim:** Prevent, Detect, Mitigate, Respond - MIT Solve is seeking tech innovations that can slow and track the spread of an emerging outbreak, for example by improving individual hygiene, developing low-cost rapid diagnostics, analyzing data that informs decision making, and providing tools that support and protect health workers. Solve is also seeking solutions that focus on preventative and mitigation measures that strengthen access to affordable primary healthcare systems, enhance disease surveillance systems, and improve healthcare supply chains.

**See:** <https://solve.mit.edu/challenges/health-security-pandemics>

**Funding Pool:** >\$1.5 Million

**Deadline:** June 18, 2020

**Solve Challenge Finals:** September 20, 2020 ; 12:00 EDT

**How to Apply:** <https://solve.mit.edu/solution?id=g3>

---

### **California Institute for Regenerative Medicine**

#### **Special Call for COVID-19 Projects**

**See:** [https://www.cirm.ca.gov/sites/default/files/files/funding\\_page/COVID19-SA\\_o.pdf](https://www.cirm.ca.gov/sites/default/files/files/funding_page/COVID19-SA_o.pdf)

**Aim:** CIRM is issuing this special announcement to support promising discovery, preclinical and clinical trial stage projects that could quickly advance treatments to COVID-19 patients in need. CIRM is utilizing its established partnering opportunities across Discovery (DISC2), Translational (TRAN1), and Clinical (CLIN1, CLIN2) stages to provide support for COVID-19 related projects.

**Interests:** (1) Proposals for development or clinical testing of a device or tool candidate will not be supported, except under the DISC2 opportunity. (2) Manufacturing of product to supply a follow-on clinical trial. (3) Any activity unrelated to development or testing of a therapeutic for COVID-19.

**Due Date:** Bi-monthly, ongoing

**Fund:** CIRM has allocated a total of \$5 million

**Awards:** \$150,000 – \$750,000 (Clinical Trial CLIN2 \$750,000 24 months; Late stage preclinical CLIN1 \$400,000 12 months; Translational TRAN1 \$350,000 12 months; Discovery DISC2 \$150,000 12 months)

---

### **CoVent-19 Challenge**

**Sponsors:** (1) Stratasys (<https://www.stratasys.com/>) and (2) Ximemica (<https://www.ximemica.com/>)

**See:** <https://www.coventchallenge.com/>

**Aim:** The CoVent-19 Challenge is fostering the innovation of a rapidly deployable, minimum viable mechanical ventilator for patients with COVID-19 related ventilator-dependent lung injury. This is an open innovation 8-week ventilator design and prototyping for engineers, innovators, designers, and makers. The two round challenge aims to create ventilator CAD assemblies by May 1, 2020 (Round 1: General Admission) and functional prototypes demonstrating acceptable performance by June 1, 2020.

**Round 1 (Open Entry):** April 1, 2020 – May 1, 2020 (The deadline for joining Round 1 is the submission deadline on May 1, 2020)

**Round 2:** (Invite Only Round): May 5-27, 2020 (Teams will be invited to Round 2 by May 4, 2020).

**Winning Design Announced:** June 1, 2020

**Awards (Prizes):** Prize Winnings (\$10,000) - First Place: Stratasys to provide \$6,500 in Stratasys Direct Manufacturing credit; Second Place: Stratasys to provide \$2,500 in Stratasys Direct Manufacturing credit; Third Place: Stratasys to provide \$1,000 in Stratasys Direct Manufacturing credit. Stratasys Direct prize amount expires on 12/31/2020. Orders must ship on or before 12/31/2020.

**To Enter Challenge:** <https://grabcad.com/challenges/covent-19-challenge-round-1>

**Due Date:** May 1, 2020

**Awards:** Resources and funds will be provided for invited teams to finalize their design and creating functional prototypes.

---

### **Amazon Web Services (AWS) Diagnostic Development Initiative (DDI)**

**See:** <https://aws.amazon.com/government-education/nonprofits/disaster-response/diagnostic-dev-initiative/>

**Aim:** The AWS Diagnostic Development Initiative (DDI) provides support for innovation in rapid and accurate patient testing for 2019 novel coronavirus (COVID-19), and other diagnostic solutions to mitigate future outbreaks. AWS is offering technical support and providing AWS promotional credits to

support the use of AWS services to advance diagnostic research for selected institutions and companies.

**Due Date:** Submissions accepted until 6/30/2020. Funding decisions will be made within 45 days of submission.

**Awards:** Promotional credits to be put toward AWS resource usage.

---

### **Fast Grants**

**Fast Funding for COVID-19 Science:** Fast Grants are available exclusively to PIs at academic institutions already working on COVID-19 related projects that could help with the pandemic within the next six months. The grants are currently supported by: John Collison, Patrick Collison, the Crankstart Foundation, Kim and Scott Farquhar, Paul Graham, Reid Hoffman, Fiona McKean and Tobias Lütke, Yuri and Julia Milner, Elon Musk, Chris and Crystal Sacca, and others. AWS has contributed compute credits.

**See:** <https://fastgrants.org/>

**Topics:** All COVID-19 related science

**Due Date:** Rolling, award decisions made in 48 hours.

**Fund:** Fast Grants funders have committed over \$16M to funding Fast Grant awardees.

**Awards:** \$10,000 – \$500,000

**Current Status:** Due to receipt of a very large number of qualified submissions, Fast Grant applications are currently closed. We may reopen them in the future. Sign up if you'd like to be notified if we reopen them:

---

### **Patient-Centered Outcomes Research Institute (PCORI)**

**Fund:** PCORI Funding Opportunity for COVID-19-Related **Enhancements to Existing PCORI-Funded Research Projects**

**See:** <https://www.pcori.org/funding-opportunities/announcement/covid-19-related-enhancements-research-awards>

**Aim:** PCORI is supporting enhancements to existing research awards that can be initiated quickly to influence the outcome of the current pandemic and that have some relationship to the original award, using existing teams that are currently funded by PCORI. Enhancements may include: modest additions to existing aims (such as additional outcomes to be collected as they relate to COVID-19), or an adjunct project that has some relationship to the original award, including a new aim (or aims) designed to produce useful knowledge related to COVID-19 and the original award. Simultaneous adaptation of original aims to account for COVID-19 may also be proposed. Taking advantage of natural experiments in health system, state, and provider responses is strongly encouraged.

**Restrictions:** PCORI seeks investigator-initiated proposals to address the COVID-19 public health crisis through enhancements of currently funded PCORI research awards. Only PCORI-funded principal investigators with active research project funding contracts are eligible to submit a proposal in response to this announcement.

**Due Date:** Proposals will be considered on a rolling basis, expected to be every two weeks, until Enhancements relating to COVID-19 are no longer warranted. Applications are due Friday, May 22, 2020 by 5:00 p.m. ET.

**Awards:** \$500,000 for Research Projects (\$500,000 limit (direct and indirect costs)—higher amounts will be considered on a case-by-case basis, based on applicants' justification of the proposed amount; \$150,000 for Engagement Awards

---

### **Patient-Centered Outcomes Research Institute (PCORI)**

**Engagement Award Special Cycle:** Engagement Awards Funding Cycle to Address COVID-19

**See:** <https://www.pcori.org/funding-opportunities/announcement/engagement-award-special-cycle-covid-19>

**Topic:** Following a Board of Governors vote early this month, PCORI is putting additional pieces in place to solicit innovative projects from the nation's investigators and healthcare stakeholder communities. To complement these PCORI-wide efforts, we committed existing Eugene Washington PCORI Engagement Awards funding to a special opportunity: Supporting Engagement in and Dissemination of PCOR/CER in the Context of COVID-19.

**Fund:** Up to \$21 million in fiscal year 2020 as part of the Eugene Washington PCORI Engagement Awards. These awards are for research support rather than a research funding opportunity.

**Online System Opens:** April 20, 2020

**Application Deadline:** May 22, 2020, 5 pm ET

**Earliest Start Date:** July 1 or August 1, 2020

**See "Applicant Training":** <https://www.pcori.org/funding-opportunities/applicant-training>

**Awards:** Vary per proposed initiative

---

### **PCORI COVID-19 Targeted PFA**

#### **Notice of Upcoming PCORI Funding Announcement (PFA)**

**Memo:** This PCORI Funding Announcement will open on Tuesday, May 5, 2020, with more information about the funding opportunity.

**See:** <https://www.pcori.org/funding-opportunities/announcement/covid-19-targeted-pfa>

**Aims:** The objectives of this announcement are to (1) strengthen the understanding of different approaches to mitigate the impact of COVID-19 on individuals, communities, healthcare providers, and healthcare systems; and (2) provide evidence to inform clinical and public health responses, decision making, and planning.

**Three Priority Areas:** (1) Adaptations to healthcare delivery (2) Impact of COVID-19 on vulnerable populations (3) Impact of COVID-19 on healthcare workforce well-being, management, and training (Although PCORI will not fund basic science research, applications proposing COVID-19-related research in areas not covered by these priorities may also be submitted. Proposals responsive to the targeted priority areas will, however, be given preference.)

**Fund:** \$30 million. This PFA may be re-issued if funds are available.

**Awards:** \$5.0 Million

**Project Period:** Two Years

**Online System Opens:** May 5, 2020

**Application Deadline:** May 26, 2020

**Merit Review:** June 2020

**Awards Announced:** July 2020

---

### **Wellcome, Bill & Melinda Gates Foundation, and Mastercard**

#### **The COVID-19 Therapeutics Accelerator**

**Aim:** Catalyze acceleration and evaluation of new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term.

**Fund:** Up to \$125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments.

**See:** <https://www.gatesfoundation.org/Media-Center/Press-Releases/2020/03/COVID-19->

**Topics:** The Accelerator is seeking partners for the following activities:

- Identify candidate compounds by testing approved drugs for activity against COVID-19,
- Screening libraries of compounds with confirmed safety data; consider new investigational compounds and monoclonal antibodies.



- Develop drugs or monoclonal antibodies that pass initial screening.
- Scale up production and commercialization of successful drugs and monoclonal antibodies.

**Due Date:** Not Specified

**Budget:** Not Specified; Total Program Budget – \$125,000,000

---

**See Also:**

**PAR-19-099 – Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional)**

**Organization:** National Center for Advancing Translational Sciences (NCATS)/NIH

**See:** <https://grants.nih.gov/grants/guide/pa-files/PAR-19-099.html>

**Type:** U01 Research Project – Cooperative Agreements

**Due Dates:** July 10, 2020; November 9, 2020; March 8, 2021; July 9, 2021

**Awards:** \$400,000 – \$750,000

---

**PAR-19-100 – Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional)**

**Organization:** National Center for Advancing Translational Sciences (NCATS)/NIH

**See:** <https://grants.nih.gov/grants/guide/pa-files/par-19-100.html>

**Type:** U01 Research Project – Cooperative Agreements

**Due Dates:** July 10, 2020; November 9, 2020; March 8, 2021; July 9, 2021

**Awards:** The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

---

**PAR-19-337 – Limited Competition: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional)**

**Organization:** National Center for Advancing Translational Sciences (NCATS)/NIH

**See:** <https://grants.nih.gov/grants/guide/pa-files/PAR-19-337.html>

**Aim:** Competitive revision (formerly known as competitive supplement) applications from **awardees with active Clinical and Translational Science Award (CTSA) Program hub awards (UL1)**. Proposals are to repurpose existing therapeutics to concentrate on the 2019 Novel Coronavirus Disease (COVID-19); deliver innovative processes to identify the therapeutic/indication pair for use to treat COVID-19.

**Type:** U54 Specialized Center- Cooperative Agreements

**Due date:** September 25, 2020, September 27, 2021, by 5:00 PM local time of applicant organization

**Awards:** Limited to no more than \$750,000/year in direct costs excluding consortium/contractual F&A costs

---

**PAR-17-465 – Bench Testing Therapeutic/Indication Pairing Strategies (UG3/UH3)**

**Organization:** National Center for Advancing Translational Sciences (NCATS)/NIH

**See:** <https://grants.nih.gov/grants/guide/pa-files/PAR-17-465.html>

**Aim:** Pre-clinical studies to **repurpose existing experimental or FDA approved drugs or biologics (existing therapeutics) that have already begun or completed at least a Phase I trial**. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include independent crowdsourcing strategies (e.g., <http://www.ncats.nih.gov/ntu/assets/current>, <http://openinnovation.astrazeneca.com/>, or any website that lists experimental therapies), or use of computational algorithms.

**Type:** UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement

**Due Dates:** June 26, 2020, by 5:00 PM local time of applicant organization.

**Awards:** Application budgets need to reflect the actual needs of the proposed project but may not be greater than: UG3: up to \$200,000 direct costs/year; UH3: up to \$100,000 direct costs.

---

**PA-18-462 – Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34) (Clinical Trial Not Allowed)**

**Organization:** National Center for Advancing Translational Sciences (NCATS)/NIH

**See:** <https://grants.nih.gov/grants/guide/pa-files/PA-18-462.html>

**Aim:** The U34 award will support clinical trial planning. This includes collection of feasibility data and complete planning, design, and preparation of the documentation necessary for implementation of Phase I and/or Phase II clinical trials for a new therapeutic use. The clinical trial that is being planned must aim to **repurpose existing drugs or biologics (therapeutics) that have already completed at least a Phase I trial for a different indication** (like COVID-19) by the time a clinical trial planning award is made. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair.

**Type:** U34 Planning Cooperative Agreement

**Due Dates:** Standard dates apply, by 5:00 PM local time of applicant organization: June 16, 2020 & October 16, 2020

**Awards:** Budgets may not exceed \$225,000 direct costs.

---

**PAR-18-332 – Clinic Testing Therapeutic/Indications Pairing Strategies (U01 Clinical Trial Required)**

**Organization:** National Center for Advancing Translational Sciences (NCATS)/NIH

**See:** <https://grants.nih.gov/grants/guide/pa-files/PA-18-332.html>

**Aim:** Support of clinical studies to repurpose existing drugs or biologics (therapeutics) that have already completed at least a Phase I trial for a different indication by the time an award is made. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic & indication pair. Projects should be supported by scientific evidence that modulation of a therapeutic target will have a positive impact on the disease/condition.

**Type:** U01 Research Project – Cooperative Agreements

**Due Dates:** June 5, 2020 & October 5, 2020

**Awards:** The budget is expected to be not more than \$3,000,000 direct costs/year.

---

**Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus**

**Notice Number:** NOT-TR-20-016

**See:** <https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-016.html>

**Organization:** National Center for Advancing Translational Sciences (NCATS)/NIH

**Type:** PA-18-591 Administrative Supplement to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

**Aim:** Research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines. A multi-organ on chip approach is strongly encouraged. Applicant must document access to a BSL-3 facility or include scientific justification for use of alternative facilities, for example using an engineered a COVID-19 pseudovirus that expresses the key surface Spike protein, which mediates its entry into cells.

**Due Date:** Rolling; First Available Due Date: May 15, 2020

**Expiration Date:** January 26, 2022

**Awards:** limited to no more than 25% total costs of the amount of the current parent award and must reflect the actual needs of the proposed project and be reasonable with respect to the activities proposed.

---

**PA-20-135 – Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)**

**See:** <https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html>

**Organization:** National Institutes of Health

**Type:** Emergency Notices of Special Interest (NOSIs) issued by the respective ICs will specify the activity codes under which recipients can apply.

**Aim:** Applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional, or national disaster. Applications in response to Emergency Notices of Special Interest (NOSIs) will be routed directly to the NIH awarding component signed on to the Emergency NOSI. Only applications submitted in response to an Emergency NOSI published by an IC will be allowed to apply to this FOA.

**Due Date:** See the Emergency Notice of Special Interest (NOSI) for any applicable Application Due Dates.

**Expiration Date:** March 10, 2023

**Awards:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

---